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Abstract
Introduction: The management of pediatric high grade osteosarcoma is lacking new approaches to classify
closely the patients and adapt thereafter the treatment initially or post-operatively. The objective of this study was to
estimate the impact of the tumor molecular response comparatively to initial biopsy and to see if this molecular
analysis was correlated to the histological response to neoadjuvant chemotherapy and/or prognosis.
Material and methods: 33 patients were included and allelotyping analyses using 23 micro satellites were
performed on biopsy’s and tumor’s DNA versus normal blood DNA. Allelic imbalances were detected in all biopsy
samples and the number of persistent AIs or not were quantified on tumors after pre-operative chemotherapy.
Results: We identified 4 subgroups with a significant impact on survival. The first group presents a complete
disappearance of the AIs and a complete response independently from the histopathologic measure for tumor
necrosis. The second group showed a partial response with persistence of some rearrangements after treatment.
The third and the last one were characterized by the same molecular profile even more rearrangements, allowing to
considered those subgroups as highly resistant osteosarcomas. This molecular re-stratification was associated with
a significant impact on survival and provides evidence that this new approach on tumor resection might be a
complementary and useful tool combined with histological response assessment.
Keywords: Osteosarcoma; Response to chemotherapy; Prognostic
marker; Allelotyping
Introduction
As the prognosis and survival seem to be stable among all protocols
since almost two decades, new approaches to re-classify closely
pediatric patients diagnosed for high grade osteosarcoma at diagnosis
and on primitive tumor grading are highly needed. The only
stratification marker at diagnosis is the presence of metastases, which
are diagnosed in almost 20% of patients and seem to contribute to a
worse prognostic [1-4]. Multiple molecular studies were performed to
obtain new diagnostic markers but, for instance and to our knowledge,
no surrogate biomarker is used in the current and ongoing
management of pediatric osteosarcomas at diagnosis in the world.
Even in the more recent publications, those markers can cover a
specific biomarker, as well as multiple bio-profiles studied by
innovative techniques but without any immediate use in the patient
routine [5-8]. Furthermore, the high genome instability of
osteosarcomas is not facilitating the establishment of one or several
markers, which could be routinely used. The second prognostic
marker is the histological response or Rosen’s grading, to neoadjuvant
chemotherapy, calculated on the surgical resection. An estimation of
less than 10% of tumor viable cells is considered as a good response to
chemotherapy (GR) and significantly linked to a better prognosis
throughout the multiple international protocols [3,4,9-12]. Even
though, among those GR patients, 10 to 15% will relapse in a
metastatic setting and/or with a rarer local recurrence. No histological
features or biomarkers were known to predict in the good responders
to treatment those relapses. In parallel, in the poor responders to
chemotherapy, no analyses highlighted the markers of patients who
will relapse or have a long-term survival. Current therapeutic
strategies for osteosarcoma patients relied on this stratification of
patients into risk categories, but, ideally, minimizing therapy for some,
while expanding treatment for others, this management should
optimize osteosarcoma treatments and reduce histological grading
limits. Therefore, multiple histological and molecular analyses were
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performed, but no potential marker for instance can be used in a
prognostic manner to screen more accurately children with high grade
osteosarcomas. The difficulties encountered with such studies are the
tumor collections, where the paired biopsic and surgical samples
should be available for comparison. The major problem to refine this
histological classification is to find the biomarkers able to do this re-
stratification on primitive tumors if the necrotic cells are highly
represented. In the Lab, since 10 years, we developed molecular
analyses based on simple and routinely done allelotyping technique for
the study of Lynch syndromes. This sensitive method is based on the
comparison between the paired DNA of the tumor and a normal
tissue, usually patient’s blood. A first publication by our group in 2003
[13], on 13 patients, was showing preliminary data comparing the
genetic profiling by allelotyping on paired biopsies and post-
chemotherapeutic tumor specimens. These preliminary analyses
revealed in case of persistence or appearance of rearrangements in
good responders to chemotherapy a lower survival rate and an
increase of relapse. To confirm those data, we progressively increased
the number of paired samples to finally obtain a cohort of 33 patients
homogeneously treated with the French OS94 protocol. Comparing
normal and tumor DNAs, the allelotyping analyses are identifying
directly the presence of chromosomal alterations and is able to detect
either chromosomal (allelic imbalance or AI) or microsatellite
instabilities (MSIs). In the entire previously published cohort of 105
pediatric osteosarcomas [14], no MSIs, identifying usually a repair
error phenotype, were detected, but only AIs were observed on
biopsy’s DNA. Twenty-three different microsatellites were analyzed on
all specimens to screen tumor response to chemotherapy at a
molecular level based on the presence or not of diagnostic AIs.
Subsequently, the objective of our study was to determine at a DNA
level the tumor response and to see if this molecular analysis and
response were correlated to the histological response to neoadjuvant
chemotherapy and its prognosis.
Materials and Methods
Patients’ data
33 pediatric patients (≤18 years) were included in this study from
November 1994 to December 2004. They were treated homogeneously
with the French OS94 protocol (included in the protocol or treated
based on the OS94 guideline after 2001) [4]. 23 patients underwent
their tumor surgery after neoadjuvant chemotherapy in the University
Hospital of Strasbourg. The 10 remaining patients were treated in the
Curie Institute in Paris (3 patients), Leon Berard Centre in Lyon (3
patients), Hospital of Trousseau in Paris (2 patients) and
GustaveRoussy Institute (2 patients). This study was conducted in
accordance with the Declaration of Helsinki. Among the 33 children,
16 were good responders and 17 poor responders to chemotherapy.
The histological grading was done as required in the SFOP-OS94
protocol [4], where a good response was defined as an estimation of
less than 5% of viable tumor cells. Clinical details (age, sex and
metastatic status) and histological response characteristics of this
population are detailed in (Table 1). Overall survival (OS) was
calculated as the period from diagnosis to death or last follow-up and
event-free survival (EFS) was calculated as the period from diagnosis
to first relapse or progression.
Tumors and biopsie’s collection
After the histological assessment by the pathologist, 33 paired
samples, where blood DNA, biopsy DNA and tumor DNA were
provided for the same patient, were included in the study. All
diagnostic biopsies and all tumors after local surgery were fresh-frozen
and stored at −80°C. Control tissues were obtained from peripheral
blood conserved on Whatman paper at room temperature.
Patients Characteristics
Age in Years 13.5 (4-18)
Sex Female 13
Male 20
Histological response to chemotherapy
GR 16
Grade IV 4
Grade III 12
PR 17
Metastatic Status 2 with lungs metastases
survival 21 alive
12 dead (2 metastatic diseases)
OS Median in months 85
At 5 Years 72%
At 10 Years 64%
EFS Median in months 79
At 5 Years 61%
At 10 Years 54%
Table 1: patient’s clinical characteristics
Tumor tissues and blood paired DNAs were purified as already
described [13]. Biopsy and tumor genomic DNA concentrations were
quantified by fluoro spectrometry (NanoDrop 3300, Thermoscientific,
Wilmington, USA), ranging from 25 to 400 ng/µL, whereas blood
DNA concentrations were ranging from 1 to 10 ng/µL. The
quantification is following the PicoGreen® assay protocol. The good-
quality DNA was assessed by the fluorometer ratio (A260/A280) and
those ratios were between 1.6 and 2.0 for all biopsies and tumors’
DNAs.
Microsatellite analyses
Twenty-three different microsatellites were analyzed on blood,
biopsy and tumor resection DNA of each patient. These microsatellites
were as follows: TP53, RB1, D2S2176, D2S2348, D3S1283, D3S700,
D4S2996, D4S428, D5S346, D5S492, D7S486, D7S667, D7S2495,
D7S2559, D7S2532, D7S1683, D8S1778, D8S1018, D9S171, D17S800,
D17S1818, D20S107, D20S855 (see primer description at http://
www.ncbi.nlm.nih.gov/genemap99 and http://www.gdb.orgwebsites) and are
targeting the following and respective loci:17q13, 13q14, 2q37, 3p24,
4q12, 5q21-31, 7q31, 7p21.2, 8q22, 9p21, 17q21 and 20q12. DNAs
Citation: Christelle L, Marie L, Luc M, Marie-Pierre C, Perrine M, et al. (2015) Molecular Reclassification in Pediatric Osteosarcomas at Surgical
Resection is a Potential Helpful Prognostic Marker. J Mol Biomark Diagn 6: 229. doi:10.4172/2155-9929.1000229
Page 2 of 6
J Mol Biomark Diagn
ISSN:2155-9929 JMBD, an open access Journa Volume 6 • Issue 2 • 1000229
originated from blood, biopsy and tumor samples (10 ng) were
amplified by PCR in a total volume of 25 µL using 0.125 µL of Taq
polymerase and 4 pmol of both forward and Cy5 labeled reverse
primers. PCR was carried out in an Omnigen Hybaid Thermocycler
(Hybaid Ldt, Ashford, UK) using the protocols already described in
our previous publications [13-17]. The PCR products were analyzed by
capillary electrophoresis on ABI PRISM® Genetic Analyzer 3100
(Applied Biosystems, Foster City, CA, USA). The data were analyzed
with the Genemapper Software (Applied Biosystems). This technique
detects two types of rearrangements: a modification of the allele ratio
in tumor or biopsy DNA compared to the paired blood DNA, which is
described as an allelic imbalance (AI), and the microsatellite instability
(MSI), which was not described in the entire French osteosarcoma
cohort [13-17]. The AI is the witness of a deletion or an amplification
of the targeted locus. An allelic variation above a cut-off of 20% is
defining the presence of a significant AI [13]. Each alteration was
confirmed by a duplicate PCR.
Statistics
Data were computed using SPSS 16.0 for Windows (SPSS, Inc.,
Chicago, IL, USA). The chi2 test was performed to analyze correlations
between subgroups based on presence or absence of allele typing
rearrangements and clinical data. Survival analysis was estimated using
the Kaplan-Meier test for overall survival and event free survival
calculations. Multivariate survival analysis was conducted using Cox
regression proportional hazards and a 95% confidence interval (CI). A
p value of less than 0.05 was considered to indicate statistical
significance.
Results
To find out if the study is suitable with the samples obtained from
the biopsies and surgical resections, we validated, first, the DNA’s
quality and, thereafter, the consistency of these patients with the
SFOP-OS94 population. Based on these pre-requisites, we went further
with the analyses to identify 4 subgroups of patients, who were
significantly linked to prognosis and outcome.
The DNAs’ quality and patients’ clinical data were relevant
for further analyses
The 33 patients were selected on the availability of fresh-frozen
samples concomitantly at diagnosis and at surgical resection after
neoadjuvant chemotherapy. Reproducible PCR products (from 73 to
300 base pairs) were detected on electrophoretic gels in all resected
tumors’ samples. These reproducible analyses showed, even on high
necrotic specimens, the possibility to amplify correctly tumor DNA in
those samples and allowed to compare in each patient the blood,
biopsy and tumor’s DNAs, if the DNA concentrations were low and
when bigger PCR products were amplified. Those results were
especially conclusive in the four patients presenting a grade IV without
any macroscopic residual osteosarcoma viable cells observed at
histological assessment and, consequently, a very high percentage of
necrosis. All the 23 microsatellites could be PCR-amplified in all
samples and the products were separated on gels at the expected sizes,
described by the manufacturer and usually observed in high quality
DNA. The microsatellites were considered as informative as they are
providing heterozygous results and, consequently, characterized by the
presence of 2 interpretable peaks, representing the two amplified
alleles of the targeted locus. All samples across osteosarcomas included
in this study were informative for at least six rearranged heterozygote
microsatellites and, thus, allowed a contributive comparison between
biopsy and tumor resection. Twenty-six out of the thirsty-three
biopsies presented 10 to 18 rearranged microsatellites. All those
findings demonstrated, firstly, that all DNAs were interpretable and,
secondly, that our selection of microsatellites represented a reliable
and sensitive tool in the tumor samples, even when they were highly
necrotic specimens.
For the cohort validation, it was difficult to compare the entire
population of the SFOP-OS94 protocol [4] to this selection of patients,
based on the availability of specific tumor samples. Nevertheless, the
clinical data were revealing an equivalent proportion of 16 GRs and 17
PRs to chemotherapy. Among the GRs, 4 patients were diagnosed as
grade IV and 12 were presenting a modified grade III response to
chemotherapy (less than 5% of tumor viable cells after neoadjuvant
chemotherapy). The overall survival (OS) in our reduced population of
33 patients was 75% at 5 years and 67% at 10 years after diagnosis. The
five-year event-free survival (EFS) was 61% and decreased to 56% at 10
years. The median follow-up was 97 months. These outcome results
were similar to the findings described in the published SFOP-OS94
trial [4]. The only discordant result was the absence of tumor response
impact in the selected population of 33 patients. There was in this
small cohort no statistical significant difference in terms of OS and
EFS based on histological response stratification (p=0.41 and p=0.56,
Figures 1A and 1B). Among the entire cohort, the metastatic status
was considered as a significant prognostic clinical marker: only 2
patients had a lung metastatic disease and both died from metastatic
relapses.
Figure 1: (A and B) are showing the absence of prognostic impact
of histological response on tumor after treatment in pediatric
osteosarcomas in this population of 33 patients.
The allelotyping analyses re-stratified the 33 tumors after
chemotherapy in 4 subgroups
Comparing the rearrangements present or absent in the biopsy’s
DNA and those in the paired-resected tumor’s DNA, we identified 4
subgroups of osteosarcomas independently from the histological
response assessed on the completely resected primary tumors.
The first subgroup (Table 2) comprised four patients (3 GRs and 1
PR). These children had a complete disappearance in their tumors
after treatment of all allelic imbalances (AIs) present at diagnosis on
the biopsy samples. The unique PR patient was a histological grade II
and did not relapse with a follow-up of 194 months. The three GRs
Citation: Christelle L, Marie L, Luc M, Marie-Pierre C, Perrine M, et al. (2015) Molecular Reclassification in Pediatric Osteosarcomas at Surgical
Resection is a Potential Helpful Prognostic Marker. J Mol Biomark Diagn 6: 229. doi:10.4172/2155-9929.1000229
Page 3 of 6
J Mol Biomark Diagn
ISSN:2155-9929 JMBD, an open access Journa Volume 6 • Issue 2 • 1000229
were divided in one grade IV and two patients with a modified grade
III. All four patients were long term survivors with an OS and EFS of
100% and might be considered as a group of complete responders to
chemotherapy based on molecular analyses of the resected tumors.
The second subgroup of fifteen patients (Table 2) showed on the
resected tumors’ DNAs a partial disappearance of the AI present at
diagnosis on the biopsies’ DNAs. The eight GRs and seven PRs of this
group had a 5-year OS of 92% and 5-year EFS of 80%. Two children
(one grade III GR and one PR with initial metastatic disease) died after
a metastatic relapse and one GR is still in second complete remission.
The number of residual AI in this partial normalized group was not
significantly linked to survival or relapse risk. The only trend observed
in the statistical analyses was the presence of residual AI located on
chromosome 7(D7S486, D7S667, D7S2495, D7S2559, D7S2532,
D7S1683) in most of the 13 alive patients (7/13) (p=0.08). This
subgroup might comprise patients, who would be considered as partial
molecular responders on tumor analyses or good molecular
responders.
The third subgroup (Table 2) was composed of seven patients, who
were maintaining the same rearrangements in the tumor’s DNA
comparatively to the biopsy’s DNA. The persistent AIs after
chemotherapy were, then, observed in five PRs and two grade III GRs,
among which five patients relapsed and four out of five died after a
second line therapy. The 5-year OS was 43% and the 5-year EFS was
29%. The two long-term survivors were one GR and one PR, with a
respective follow up of 159 and 111 months. Those osteosarcomas
might be stratified as resistant cancers at the molecular level
independently from the histological response assessment or
considered as molecularly poor responders to chemotherapy.
4 Subgroups Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4
Molecular status Complete normalisation Partial normalisation Same profile New rearrangements
33 patients 4 patients
3 GRs
1 PR
15 patients
8 GRs
7 PRs
7 patients
2 GRs
5 PRs
7 patients
3 GRs
4 PRs
5-year OS
5-year EFS
100%
100%
92%
80%
43%
29%
15%
15%
p= 0.0003
p=0.002
p=0.001
p=0.0001
p=0.0001
Alive
Dead
4
0
13
2
3
4
1
6
Median survival
(months)
event
155
no event
119
2 events
39.5
4 events
24.5
6 events
Table 2: Characteristics of the 4 subgroups identified with the allelotyping analyses comparing biopsy and tumor molecular rearrangements.
The last subgroup clustered seven patients (Table 2). Their tumor
samples after chemotherapy were characterized by the detection of
new DNA rearrangements, which was not detected on the diagnostic
biopsy. All tumors, except one, had at least three new detected AI
comparatively to diagnosis status. Six, 3 GRs and 3 PRs, out of seven
patients were relapsing and, finally, died after second line therapy. The
only remaining patient is still in complete remission 125 months after
diagnosis, was initially a PR with a localized osteosarcoma and
presented only one new AI in her resected osteosarcoma. The 5-year
OS and EFS are dramatically low at 15%. In this small population, no
statistical link was highlighted based on the location of the newly
rearranged loci, except for 5q21-31, where a trend was observed
(p=0.07). Three out of seven tumors were adding a new AI in the
5q21-31 locus (D5S346, D5S492) comparatively to the initial panel of
rearrangements in the paired biopsy. In this group, the neoadjuvant
treatment seems to select a new and resistant tumor cell clone.
Nevertheless, the long term survivor was only showing one new single
AI and presented a partial response on the others AIs, as described in
the second subgroup of partial molecular responders. No other patient
of this subgroup had this molecular profile. The 6 dead patients
retained all previous AIs, which were described on the biopsy sample
and accumulated at least 3 new AIs. This subgroup should be
considered as a selection of highly resistant osteosarcomas, especially
in case of maintenance of all previous genomic abnormalities plus new
DNA AIs.
Figures 2: (A and B), showing the statistical significance was
present for overall survival (OS, p=0.003) and for event-free
survival (EFS, p=0.002) and linked the 4 molecular subgroups to a
prognostic significance. (Green line=complete molecular response,
pink line= partial molecular response, yellow line=poor molecular
responders and black line=highly resistant tumors with appearance
of new cellular clones).
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This re-stratification by molecular allelotyping was
significantly related to survival, but not to histological
response to chemotherapy
The correlation between the different molecular subgroups of
resected tumors and overall and event-free survival was statistically
significant (p=0.003 and p=0.002, respectively) (Figures 2A and 2B).
An increase of relapses was significantly linked to the subgroups of
molecularly poor responders(third subgroup) and in case of new cell
clone appearance and correlated with the increase of deaths (Table 2
and Figure 3A, Khi-deux test, p=0.0001). This molecular re-
stratification was significantly linked to survival and had a prognostic
impact in univariate analyses, as well as the metastatic disease status at
diagnosis. The variables, identified as independent factors affecting
patient survival, were including the presence of metastasis (HR, 5.589;
95% CI, 1.561–20.013; p=0.008) and the molecular re-stratification
(HR, 3.709; 95% CI, 1.770–7.774; p=0.001). Surprisingly, this
molecular response was not statistically related to the histological
response assessment (Figure 3B, p=0.48), but seems to reclassify the
PRs with better outcome in the good molecular responders and the
GRs with worst outcome in the poor molecular responders.
Figures 3: (A) is presenting the statistical correlation between the 4
subgroups of molecular response on tumor resection and the
percentage of deaths in each subgroup of molecular response. In
the (B), no correlation was highlighted between the molecular
responses and the histological response on tumor resection.
(Normal=complete molecular tumor response, partial=partial
molecular response in the surgical resection, same profile=poor
molecular responders with the persistence of same molecular
rearrangements and new clone=resistant tumors with the
appearance of new cellular clones after neoadujvant treatment).
Discussion
This study aimed to identify how the molecular analyses of the
resected tumor’s DNA could help to re-stratify the tumor histological
grading, as GRs and PRs, and whether its results might add additional
prognostic information. Interestingly, this molecular evaluation is
based on a simple, rapid and routinely done technique, which can be
used on samples with a low percentage of cells, like on tumor surgeries
after neoadjuvant chemotherapy, and still remains informative. The
PCR product amplifications were reproducible with applicability to
surgical samples after treatment. All samples could be analyzed
accurately. Badly, even the survival statistical analyses were consistent
with the survival analyses of the SFOP-OS94 trial [4], the histological
response to chemotherapy was not significantly linked to patient
prognosis in our small group of 33 pediatric osteosarcomas. This
discrepancy is probably due to the random choice of the 33 patients
only based on the availability of the fresh-frozen samples at diagnosis
and surgery and could have induced a statistical bias.
However, this molecular analysis, comparing the diagnostic
allelotyping profile to the resected tumor’s status after treatment,
allowed identify 4 subgroups: two groups with a complete or partial
molecular response and two highly resistant subgroups to
chemotherapy, for whom the prognostic outcome was especially bad.
These subgroups based on the molecular response after pre-operative
chemotherapy were not correlated with measurement of
histopathologic tumor necrosis on the same sample. Whereas PRs can
be complete or partial responders at molecular level and have a good
prognosis, GRs can also be at molecular level considered as resistant
osteosarcomas and relapse rapidly in those cases.
To our knowledge, this is one of the first studies analyzing
molecular status on surgery samples of pediatric osteosarcomas to
understand further, why PR may have a better prognosis and why
some of the GRs to treatment will relapse and died. Most of the
studies, even in our Lab, were focusing on diagnostic samples to
determine really early the chemoresistant osteosarcomas [5-8,13-17].
Nevertheless, this risk re-stratification is necessary to adapt the
treatment but, for instance, was mostly based on clinical features
[18-21]. The first explanation in the difficulty to find one or multiple
biomarkers useful in osteosarcoma re-stratification and risk
assessment is the complexity and the heterogeneity of this cancer
[22,23].
Therefore, our molecular analyses on the surgical samples are
overpassing such tumor cell complexity as they are simple, rapid and
independent from the diagnostic rearranged biomarkers. We have,
then, provided evidence that these simple and routinely done analyses
were feasible even in patients for whom a complete necrosis was
measured at tumor histopathology after neoadjuvant treatment. It
appeared as a useful tool to refine the histopathological response and
to determine potential PRs, who will be long term survivors, and the
GRs with a worse prognosis. So, this approach via tumor surgery
analyses seemed to allow complementary prognostic assessment with
histology, but this molecular re-stratification has to be confirmed in
larger cohorts and has to be tested on paraffin-embedded samples,
even preliminary data on paraffin-embedded versus fresh-frozen
specimens seemed to be promising.
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